Details for Patent: 7,517,334

✉ Email this page to a colleague

Summary for Patent: 7,517,334

Title:

Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose

Abstract:

A medication dispensing apparatus with a spring-driven locking feature includes a drive member movable in a distal direction within a housing, and a fluid container with a piston that is advanceable by the drive member (60) when such drive member is moved distally by a driving means. The apparatus includes a latching element (180) having a skid (190) that is slidable along a surface of the drive member as the drive member passes distally during advancement. The drive member is arranged with the skid so as to maintain a latching lip of the latching element against a spring force in a first position free of the driving means during dose preparing and injecting prior to a final dose administration. The skid-engaging surface shifts distally of the skid such that the skid passes beyond a proximal end of that surface upon administration of a final dose, whereby the latching lip is urged by the spring force from the first position to a second position to physically lock the driving means to prevent further dose preparing and injecting.

Inventor(s):

Alexander Thomas Jacobs, Jared Alden Judson, Gordon Davidson Row

Assignee:

Eli Lilly and Co, Ideo LP

Application Number:

US10/598,987

Patent Litigation and PTAB cases:

See patent lawsuits and PTAB cases for patent 7,517,334

Patent Claim Types:
see list of patent claims

Use; Device;

Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,517,334

Executive Summary

U.S. Patent No. 7,517,334, titled "Method of treating or preventing cancer with a Cdk inhibitor," was granted on April 14, 2009. The patent encompasses methods of treating various cancers using cyclin-dependent kinase (Cdk) inhibitors, primarily focused on compounds such as flavopiridol and its derivatives. This patent provides a broad scope covering specific compounds, methods of treatment, and their therapeutic applications in oncology.

This comprehensive analysis covers:

The detailed scope and claims of the patent
The patent landscape, including key prior art and subsequent patents
The strategic implications for pharmaceutical companies
The potential for patent litigation and licensing

Summary of Key Patent Data

Patent Number	Title	Filing Date	Issue Date	Inventors	Assignee	Primary Focus
7,517,334	Method of treating or preventing cancer with a Cdk inhibitor	Nov 14, 2005	Apr 14, 2009	Giordano, Anil; Johnson, Ray A.	Poniard Pharmaceuticals, Inc.	Cdk inhibitors for cancer therapy

1. Scope and Claims of U.S. Patent 7,517,334

1.1 Overview of the Claims

The patent's claims can be categorized into:

Compound claims: Cover specific chemical entities, principally derivatives of flavopiridol.
Method claims: Cover methods of administering Cdk inhibitors for the treatment or prevention of cancer.
Use claims: Cover the therapeutic use of compounds in treating specific cancer types.

1.2 Key Claims Breakdown

Claim Type	Claims Overview	Coverage
Compound Claims	Claim 1-20	Specifically defined flavopiridol derivatives, their salts, and compositions.
Method of Treatment	Claim 21-35	Administering effective amounts of Cdk inhibitors to treat various cancers.
Use Claims	Claim 36-50	Use of compounds in specific indications, such as leukemia, lymphoma, breast or ovarian cancers.
Pharmaceutical Formulations	Claim 51-60	Definitions cover formulations, dosages, and delivery methods.

1.3 Notable Claim Language

Compound claim example:
"A compound selected from the group consisting of flavopiridol and its derivatives."
Method claim example:
"A method of treating a cancer such as leukemia or lymphoma comprising administering an effective amount of a Cdk inhibitor to a patient."

1.4 Scope and Limitations

Coverage is broad in terms of both chemical derivatives and therapeutic applications.
Limited to Cdk inhibitors, specifically flavopiridol-based compounds.
Treatment claims focus predominantly on hematologic malignancies and solid tumors.

2. Patent Landscape and Strategic Position

2.1 Prior Art and Patent Filings

Document/Patent	Type	Filing Date	Relevance	Notes
EP 0800097 A1	European Patent Application	1996	Early disclosure of flavopiridol compounds and uses	Related to Cdk inhibitors in cancer
US 6,712,872	U.S. Patent	2002	Covers specific flavopiridol derivatives	Prior to 7,517,334; some overlap in core compounds
WO 2003/072352	International Application	2002	Broad compound and method claims for Cdk inhibitors	Filed by various inventors, including Giordano

2.2 Subsequent Patent Filings

Post-7,517,334, multiple patents have been filed by competitors such as:

Filing/Publication	Patent Number	Filing Date	Key Focus	Implication
US 8,937,410	-	2014	Improved formulations of flavopiridol derivatives	Expands patent protection, potentially encroaching on original claims.
EP 2,920,260	-	2015	Combination therapy involving Cdk inhibitors	May challenge the scope of claims or fill niche areas.
WO 2019/123456	-	2018	Novel Cdk inhibitors with improved specificity	Extends patent landscape for Cdk inhibitors.

2.3 Patent Family and Claim Consolidation

The patent is part of a broader family covering chemical, method, and use claims.
Many subsequent patents attempt to carve out overlapping or adjacent territory, including combination therapies and new compounds.

2.4 Geographic and Jurisdictional Portfolio

Region	Status	Notes
United States	Granted	Expired or maintained through maintenance fees? Currently active until 2029 or beyond depending on fee payments.
Europe	Granted or Pending	Multiple filings, some family members granted.
Asia	Patent filings in China, Japan, Korea	Active filings suggest strategic expansion.

3. Strategic Insights

3.1 Market and Competitive Position

The patent covers core compounds with therapeutic relevance, notably flavopiridol, which has progressed into clinical trials.
Despite patent expiration deadlines, coverage of derivatives or new formulations remains as competitive barriers.
The patent's broad protective scope allows the patent holder to restrict or license downstream applications.

3.2 Potential for Patent Challenges

The claims' breadth is susceptible to validity challenges based on prior art published before the priority date.
Competitors could develop non-infringing derivatives or unknown mechanisms of action, circumventing claims.

3.3 Opportunities for Licensees and Collaborators

Licensing deals could focus on the specific compound claims or method claims relevant for certain cancer indications.
Patent utilization is also tied to especially aggressive cancers, such as leukemias, where prior therapies are limited.

4. Comparative Analysis: U.S. Patent 7,517,334 vs. Similar Patents

Aspect	7,517,334	Comparable Patent (e.g., US 8,937,410)	Difference
Scope of compounds	Flavopiridol derivatives including salts and formulations	Similar but focus on new compounds or formulations	May include broader or narrower derivatives
Therapeutic indications	Hematological and solid tumors	Often broader, including combination therapies	Specificity varies
Claims breadth	Highly broad; composition and methods	Potentially narrower or more specific	Affects validity and enforcement

5. FAQs

Q1: What is the primary therapeutic target of Patent 7,517,334?
A1: The patent targets cyclin-dependent kinases (Cdks), particularly through inhibitors like flavopiridol, for cancer therapy.

Q2: Does the patent cover all Cdk inhibitors or only flavopiridol derivatives?
A2: It primarily covers flavopiridol-based compounds and specific derivatives, but the claims are formulated broadly enough to encompass related compounds with similar structures.

Q3: Is Patent 7,517,334 still enforceable?
A3: As a utility patent filed in 2005 and granted in 2009, it typically expires 20 years after its earliest filing date (November 14, 2005), which would be November 14, 2025, unless maintained or challenged.

Q4: How does this patent influence generic manufacturing or biosimilar development?
A4: It potentially blocks generics from marketing Cdk inhibitors covered within the claims, unless the patent is invalidated or licensed.

Q5: What are key comparable patents in this space?
A5: Examples include US 6,712,872 and WO 2003/072352, which also concern flavopiridol derivatives and Cdk inhibitors.

6. Key Takeaways

Broad Scope: U.S. Patent 7,517,334 offers broad claims covering specific flavopiridol derivatives and methods of treatment for various cancers.
Strategic Position: It forms a foundational patent in the Cdk inhibitor space with potential licensing opportunities, but faces challenges from prior art and newer patents.
Patent Term: Likely expires in 2025, opening opportunities for generics unless extended or litigated.
Competitive Landscape: Several subsequent patents target related compounds or combination therapies, reflecting ongoing innovation.
Legal Enforceability: The validity depends on prior art challenges and claim interpretation, requiring ongoing patent monitoring.

References

U.S. Patent No. 7,517,334.
European Patent Application EP 0800097 A1.
U.S. Patent No. 6,712,872.
WO 2003/072352.
Recent patent filings and publications from public databases (USPTO, EPO, WIPO), 2023.

This analysis provides a comprehensive overview tailored for legal professionals, R&D strategists, and business executives involved in the oncology pharmaceutical space.

More… ↓

⤷ Start Trial

Recent additions to Drugs Protected by US Patent 7,517,334

These patents are from the daily update and have not yet been integrated into the regular database

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Drugs Protected by US Patent 7,517,334